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Abstract
The human erythrocyte contains an abundance of the thiol-dependant peroxidase Peroxiredoxin-2 (Prx2), which protects
the cell from the pro-oxidant environment it encounters during its 120 days of life in the blood stream. In malarial infections,
the Plasmodium parasite invades red cells and imports Prx2 during intraerythrocytic development, presumably to
supplement in its own degradation of peroxides generated during cell metabolism, especially hemoglobin (Hb) digestion.
Here we demonstrate that an irreversible Prx2 inhibitor, Conoidin A (2,3-bis(bromomethyl)-1,4-dioxide-quinoxaline; BBMQ),
has potent cytocidal activity against cultured P. falciparum. Parasite growth was also inhibited in red cells that were treated
with BBMQ and then washed prior to parasite infection. These cells remained susceptible to merozoite invasion, but failed
to support normal intraerythrocytic development. In addition the potency of chloroquine (CQ), an antimalarial drug that
prevents the detoxification of Hb-derived heme, was significantly enhanced in the presence of BBMQ. CQ IC50 values
decreased an order of magnitude when parasites were either co-incubated with BBMQ, or introduced into BBMQ-pretreated
cells; these effects were equivalent for both drug-resistant and drug-sensitive parasite lines. Together these results indicate
that treatment of red cells with BBMQ renders them incapable of supporting parasite growth and increases parasite
sensitivity to CQ. We also propose that molecules such as BBMQ that target host cell proteins may constitute a novel host-
directed therapeutic approach for treating malaria.
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Introduction
Infections by the malaria parasite, Plasmodium falciparum, account
for almost one million deaths each year. Efforts to reduce the
burden of disease are hampered by the development of drug-
resistant strains [1]. Chloroquine (CQ) in particular was once a
highly effective and mainstay treatment, but is now virtually
useless in most parts of the world. The drug is understood to kill
the parasite growing inside the red blood cell by targeting the
hemoglobin digestion pathway in the parasite food vacuole.
Specifically, the drug inhibits the conversion of heme to hemozoin.
The build-up of heme generates free radicals and oxidative
molecules, including peroxides, which are toxic to the cell [2].
Many parasite strains throughout the world are now insensitive to
CQ treatment due to acquisition of variant drug transporter
proteins that expel the drug from the parasite and provide a
selective advantage under CQ exposure [3,4].
Erythrocytes are exposed to high levels of oxidative stress from
the continual autoxidation of hemoglobin, which produces O2
2
and H2O2, and free-radical generation from the lipid-rich
membrane and heme. Protection from these damaging molecules
is afforded by several enzymatic and non-enzymatic-based systems
[5]. Among these are the peroxiredoxins (Prx), ubiquitous thiol-
containing proteins that catalyze the decomposition of H2O2 to
water. Three Prx proteins are found in erythrocytes, Prx 1, 2 and
6; Prx2 is by far the most important and is the third most abundant
protein in the cell [6]. Prx2 exists as a homodimer. It decomposes
H2O2 via the oxidation peroxidatic cysteine residues (one per
monomer), resulting in the formation of cysteine sulfenic acids and
subsequent formation of an intermolecular disulfide bond.
Reactivation of the enzyme occurs through the action of
thioredoxin reductase-coupled thioredoxin, which reduces the
intermolecular disulfide bond [7].
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The Plasmodium parasite also possesses a series of endogenous
enzymatic systems to counter the high oxidant environment of the
erythrocyte in which it resides, as well as the products of its own
metabolism. They comprise of glutathione, thioredoxin and
superoxide dismutase; the parasite however lacks a catalase-based
pathway (reviewed in [8,9]). As well as studies demonstrating
essentiality of at least thioredoxin-dependent protection [10,11],
these systems may also protect the parasite from the actions of
antimalarials that induce oxidative stress. For example, early
transcriptional responses to CQ exposure include up-regulation of
these systems [12]. Inhibition of glutathione synthesis in particular
has also been shown to enhance the effect of chloroquine against
P. berghei infections in mice [13,14]. Indeed much work has focused
on these oxidant protective systems as potential antimalarial
targets (reviewed by [15]).
Recently it was suggested that thioredoxin-dependent consump-
tion of peroxides in the parasite may also be mediated by the host
red cell Prx2. Koncarevic and colleagues [16] identified Prx2
inside erythrocytic stage P. falciparum, and this has since been
confirmed in proteomic-based surveys [17]. The protein is
imported from the host cell into the parasite cytosol, where it
remains biologically active and enzymatically coupled with P.
falciparum-expressed thioredoxin. Biochemical assays indicate that
approximately half the peroxide detoxification activity in the
parasite is derived from Prx2 [16]. Interestingly, under CQ
exposure the parasite also up-regulates the import of Prx2 [16],
suggesting that not only is the host enzyme important for normal
parasite growth, but that it also functions to counteract the toxic
effects of CQ.
Here we tested if an available chemical inhibitor of 2-Cys-
containing peroxiredoxins, conoidin A (2,3-bis(bromomethyl)-1,4-
dioxide-quinoxaline; BBMQ), affects the growth of P. falciparum
parasites. BBMQ chemically reacts with the peroxidatic Cys
residues of peroxiredoxins, forming irreversibly inactive homodi-
mers. BBMQ was previously shown to inhibit human Prx2 in
epithelial cells, and the Prx2 homolog of Toxoplasma gondii. [18].
Methods
P. falciparum culture
P. falciparum strains 3D7 (chloroquine and mefloquine sensitive),
K1 (chloroquine resistant) and W2mef (mefloquine resistant), all
gifts from R. Anders and L. Tilley, La Trobe University,
Melbourne, Australia, were maintained at between 1 and 10%
parasitemia in purified AB+ human erythrocytes in a 1% O2/5%
CO2 atmosphere according to the method of Trager and Jensen
[19]. The cell culture medium (CCM) comprised of RPMI 1640
(HEPES, glucose and glutamine-free) supplemented with 1X
glutamax, 0.2% Albumax (all from Life Technologies, Australia),
4% pooled AB+ human serum (Invitrogen), 10 mM D-glucose,
25 mg/ml gentamycin, 6 mM HEPES and 0.2 mM hypoxanthine
(all from Sigma). ‘‘CCM-wash’’ lacked serum and Albumax.
Human red cells were supplied as expired red cell packs by the
Australian Red Cross Blood Service (Bloodbank). Ethical approv-
als to work with the cells were obtained from the University of
Tasmania and Macquarie University Human Research Ethics
Committees (project numbers H09004 and 5201200714, respec-
tively).
Drug treatments and parasite growth assays
Parasite cultures were synchronized prior to treatment at either
the mature pigmented trophozoite stage (using Percoll gradient
sedimentation) or immature ring stage (using two cycles of 5%
sorbitol separated by 6 hours). Parasites were seeded in CCM with
uninfected red cells at a final parasitemia of approximately 1% and
a hematocrit of 2%. CQ and BBMQ (both from Sigma Aldrich,
Castle Hill, Australia) were diluted to 56 final concentration in
CCM, and added to the prepared parasites at a volumetric ratio of
1:4. Parasite growth was determined by counting proportions of
infected cells in Giemsa-stained blood smears. Percentage growth
inhibition was calculated as the proportional difference in growth
between treated and untreated cultures. All growth assays were
performed at least twice, with duplicate or triplicate culture wells;
at least 400 cells were counted for each well.
BBMQ pretreated red cells (washout)
Uninfected red cells were treated with BBMQ for 24 hours in
CCM-wash at 4uC with constant mixing. The cells were then
centrifuged, supernatant removed and washed three times in 1006
cell pellet volume of CCM-wash. For untreated controls, cells were
incubated and washed in CCM-wash without BBMQ under
identical conditions. To check the effectiveness of the cell washing
protocol, cells were also incubated with an IC100 concentration of
CQ (100 nM) for 24 hours and similarly washed. A CQ sensitive
parasite strain (3D7) grew normally in these cells (data not shown).
We also performed experiments that showed that BBMQ
treatment had no effect on the morphology or osmotic fragility
of red cells (tested up to 25 mM; data not shown). In the CQ
treatment experiments, synchronized trophozoites were incubated
with the washout cells for 12 hours to allow merozoite invasion to
occur, after which CQ was added.
Isobologram analysis
Different fixed ratios of BBMQ and CQ (both at approximately
56 IC100 concentrations) were prepared, serially diluted, added to
parasite cultures and growth assays conducted over a 48 hour
incubation period. Stock solutions of BBMQ (250 mM) and CQ
(0.8 and 40 mM for 3D7 and K1, respectively) were mixed
together at the indicated proportions, serially diluted (2-fold) with
CCM, and then mixed at a 1:4 volumetric ratio with parasitized
cells (,1% parasitemia, 2% hematocrit in CCM. Samples were
analyzed for growth after 48 hours incubation using YOYO-1 dye
staining and flow cytometry [20].
TUNEL labeling
Thin blood smears prepared from parasite cultures were air-
dried, fixed for 30 s in methanol, fixed for 20 min in 1%
paraformaldehyde in PBS, washed in PBS, blocked and permea-
bilized with 1% BSA/0.05% Triton X-100 in PBS, and then
labeled with the TUNEL assay. TUNEL assay labeling was
performed using the Apo BrdU TUNEL Assay Kit (Molecular
Probes, Eugene, OR) using methods described in [21].
Immunobloting
Mature pigmented trophozoite stage parasitized cells were
harvested from parasite cultures using Percoll density gradient
centrifugation, and washed three times in PBS. To isolate the
intracellular parasites from the surrounding red cell, the washed
cells were treated with 0.15% saponin (106 cell volume) for
10 min on ice, and then washed 3 times with 1006volume 0.15%
saponin. The parasite pellets were suspended in SDS loading
buffer containing 100 mM dithiothreitol (DTT), sonicated
(3630 s), and then heated to 95uC for 5 min. Samples of
uninfected red cells were also prepared by addition to SDS
loading buffer (with or without DTT and N-ethylmaleimide).
Following centrifugation, the soluble fractions (20 mg per lane)
were separated on 12% SDS-PAGE gels (Biorad, Australia) under
Conoidin A and Plasmodium falciparum
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reducing conditions. Following transfer to nitrocellulose mem-
brane, they were blotted with antibodies against human Prx2,
hyperoxidized Prx2 (Prx-SO2/3) and hexokinase (all from Abcam,
Cambridge, MA), diluted in PBS/5% skim milk powder/0.05%
Tween-20 overnight at 4uC. After washing (PBS/0.05% Tween-
20), membranes were incubated with peroxidase-conjugated
secondary antibodies for 4 h at 4uC. Chemiluminescent detection
was performed using Immobilon Western Chemiluminescent
HRP Substrate reagent (Millipore) and detected using a Chemi-
Smart 5000 instrument (Vilber Lourmat).
Statistical Analysis
P values are calculated using two-tailed t-tests assuming equal
variance.
Results
Red cell Prx2 is imported into P. falciparum parasites and
inhibited by BBMQ
We first confirmed the presence of a functionally active Prx2
within intraerythrocytic-stage P. falciparum parasites grown in
culture. Saponin purified parasites contained enriched levels of the
protein, relative to another abundant cytosolic red cell protein,
hexokinase (Figure 1A). The protein was also hyperoxidized,
indicative of being enzymatically active in the parasite. Next, we
showed that BBMQ inhibits Prx2 in human erythrocytes. Similar
to the effects of BBMQ on Prx2 previously seen in human
epithelial cells [18], exposure of red cells (from expired transfusion
packs) to BBMQ induced the formation of high molecular weight
forms of Prx2 that were stable under non-reducing conditions in
the presence of N-ethylmaleimide. These effects were also
concomitant with a reduction of the monomeric protein
(Figure 1B). In addition, we analyzed the effect of BBMQ on
levels of hyperoxidized Prx2, which is normally detectable in red
cells [22]. BBMQ treatment resulted in reduced amounts of
hyperoxidized protein, consistent with its ability to covalently bind
to the peroxidatic cysteine of Prx2 and block subsequent
hyperoxidation (Figure 1C).
BBMQ is cytocidal against intraerythrocytic P. falciparum
parasites
We tested the ability of BBMQ to inhibit the growth of P.
falciparum parasites cultured in human red blood cells. The growth
of laboratory-adapted strains, either sensitive (3D7) or resistant
(K1 and W2mef) to antimalarial drugs, was inhibited by BBMQ
treatment in a dose dependent manner (Figure 2A). Similar IC50
values were also calculated. BBMQ added at .IC100 levels had
striking effects on the visual appearance of parasites. There were
obvious delays in parasite maturation, as well as parasites with
condensed, pyknotic-appearing nuclei, all indicative of stalled
growth and/or parasite death (Figure 2B). These observations
were quantified in cultures synchronized at either the mature
pigmented trophozoite stage or immature ring stage (Figure 2C).
The majority of trophozoite-stage parasites treated with BBMQ
failed to develop into schizonts and produce new merozoites.
BBMQ-treatment of ring-stage cells resulted in a marked
reduction in the progression to the more mature forms. In both
cases, these effects were obvious after just 4 hours of treatment.
Virtually all the cells in the treated cultures were growth-arrested
or pyknotic in appearance by the end of the observation period
(26 hours). A more objective analysis of this cytocidal effect was
conducted using a parasite culture-adapted TUNEL assay [21],
which detects fragmented DNA as an indicator of parasite death.
BBMQ treatment of immature rings resulted in significantly more
Figure 1. Analysis of erythrocyte peroxiredoxin-2 in P.
falciparum parasites and the effect of BBMQ treatment. (A)
Immunoblot analysis of saponin-purified P. falciparum parasites (strain
3D7) and uninfected erythrocytes (separated under reducing condi-
tions) for Prx2, hyperoxidized Prx (Prx-SO2/3) and hexokinase. Equal
numbers of cells were loaded in each lane. The presence of human
hexokinase indicates the relative level of contaminating red cell
proteins in the purified parasite fraction. (B and C) Immunoblot analysis
of the effect of BBMQ treatment of human erythrocytes on Prx2
multimer formation using anti-Prx2 antibody (B), and on total and
hyperoxidized amounts of Prx2 (C), using the respective antibodies. In
(B) proteins were extracted in the presence of N-ethylmaleimide and
separated under non-reducing conditions. In (C) proteins were
separated under reducing conditions.
doi:10.1371/journal.pone.0092411.g001
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TUNEL-labeled parasites compared to untreated cultures after 4,
17 and 26 hours incubation (Figure 2D).
P. falciparum cannot grow in cells pretreated with BBMQ
Continuously treating the parasite cultures with BBMQ in the
above experiments meant that we could not distinguish between
effects of BBMQ on host versus parasite proteins. We therefore
exploited the irreversible action of BBMQ to determine if specific
exposure of the host cell to BBMQ subsequently affected parasite
viability. Red cells were pretreated with increasing concentrations
of BBMQ and then washed (as described in Methods) prior to
parasite infection (called washout). Following addition of purified
trophozoites to the washout cells, identical proportions of ring-
stage cells were observed after 12 hours incubation, indicating that
parasite invasion was unaffected. BBMQ concentrations up to
25 mM were tested without any observable differences on invasion
(data not shown). After 48 hours incubation in the washout cells,
we noted the appearance of parasites exhibiting signs of growth
arrest (at the ring stage), and condensed and pyknotic appearing
nuclei similar to observations in the continuously treated cultures.
Analysis of cultures after 72 hours also revealed a concentration
dependent reduction in the proportion of second-generation rings
(and overall parasite growth) (Figures 3A and B). This occurred for
both the 3D7 and K1 strains, with similar IC50 values (2.2 and
3.9 mM, respectively). Compared to continuous BBMQ treatment,
the potency of BBMQ in the washout experiments was reduced
three to five fold, suggesting the inhibitory effect may be partly due
to BBMQ inhibition of parasite proteins. Taken together, the data
indicate that intraerythrocytic development of parasites is
prevented by treatment of the red cell with BBMQ. We
hypothesize that the compound targets and inactivates host
proteins that are normally required by the parasite for its growth.
Figure 2. Effect of BBMQ treatment on P. falciparum parasite growth. (A) Percentage growth inhibition for three different parasite strains
treated with BBMQ. IC50 values (6 SEM) for the effect of BBMQ were 7866136 nM (3D7), 9536188 nM (K1) and 7516174 nM (W2mef). No significant
differences (p.0.5). (B) Photomicrographs of pyknotic or growth-arrested 3D7 parasites following BBMQ treatment. Parasites were synchronized at
either the ring stage (panels i and iii) or trophozoite stage (panels ii and iv), and then treated for 12 hours with 25 mM BBMQ (panel i and ii), or left
untreated (panel iii and iv). Arrow indicates a parasite of pyknotic appearance; arrowheads indicate growth-arrested trophozoites with condensed
and fragmenting nuclei. (C) Percentage of 3D7 infected red cells (% parasitemia) categorized according to parasite developmental stage, following
50 mM BBMQ treatment for indicated times. (D) Percentage of TUNEL-labeled 3D7 parasites following treatment of synchronized ring-stage parasites
with 50 mM BBMQ for indicated times. Data shown in (A and D) represent the mean (6 SEM) of at least two independent experiments performed in
duplicate. * indicates p,0.01.
doi:10.1371/journal.pone.0092411.g002
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P. falciparum parasites are more sensitive to CQ in BBMQ-
treated cells
In response to CQ treatment, P. falciparum parasites up-regulate
the importation of host cell Prx2 [16], presumably to provide the
cell with an increased peroxide detoxification capacity and counter
the increased oxidative load imparted by the build-up of free
heme. We hypothesized that if treatment of the cell with BBMQ
inhibits the peroxiredoxin oxidant protection system, we would see
an increase in the parasite’s sensitivity to CQ. To investigate this,
we allowed 3D7 parasites to invade BBMQ washout cells (a sub-
inhibitory concentration of BBMQ was used; 250 nM), and then
treated with CQ. After 24 hours of CQ treatment, we observed
the appearance of malformed and apparently growth-arrested
trophozoite-stage parasites, the frequencies of which increased
with CQ concentration (Figures 4A and C). Across the CQ
titration range, significantly greater proportions of these growth-
arrested forms were observed in the BBMQ washout cells
compared to control cells (Figure 4B), corresponding to a ten-
fold lower IC50 for CQ (control, 16 nM; BBMQ washout,
1.4 nM). Similar experiments were conducted using a 48 hour
incubation protocol to measure the appearance of second-
generation ring-stage parasites. CQ inhibited new ring production
in a dose-dependent manner and this effect was significantly
enhanced in BBMQ-pretreated cells (Figure 4D); six to ten-fold
lower CQ IC50 values were calculated (3D7: untreated, 26 nM;
BBMQ, 2.3 nM; K1: untreated, 313 nM; BBMQ, 51 nM).
Therefore, parasites residing within red cells that have been
pretreated with BBMQ are more sensitive to CQ.
In a second set of experiments we conducted an isobologram
analysis of the 3D7 and K1 strains to determine the type of
interaction between BBMQ and CQ. Increasing proportions of
CQ had little effect on BBMQ IC50 values for both strains
(Figure 5A and C). However, IC50 values for CQ decreased
markedly (and in proportion) with increasing ratios of BBMQ
(Figure 5B and D). For example, the CQ IC50 for 3D7 decreased
from 21 nM in the absence of BBMQ to 1.2 nM in the presence of
BBMQ added at a 4:1 ratio. The same 4:1 BBMQ:CQ ratio
reduced the CQ IC50 of the K1 strain more than thirty-fold, and
effectively rendered the strain as sensitive to CQ as 3D7. The sum
of the fractional IC50 values for each strain were approximately
one (3D7: 1.01+/20.18; K1: 1.11+/20.09), indicating that the
growth inhibitory effects of the two compounds were additive.
However the additive effect occurred exclusively via the enhance-
ment of BBMQ on CQ activity, and not the reverse. We speculate
that this is due to differences in parasite stages most sensitive to
each compound. Our observations (Figure 4A) and those made
previously [23] show that the cytocidal effects of CQ are not
apparent until the later trophozoite stages of development, while
BBMQ is cytocidal against early ring-stage parasites (Figure 2C).
Discussion
In summary, we have shown that treatment of red cells with an
irreversible inhibitor of 2-Cys peroxiredoxins, BBMQ, prevents
the growth of P. falciparum and enhances the sensitivity of the
parasite to CQ. BBMQ treatment of red cells resulted in the
formation of high molecular weight forms of Prx2 (<10 mM),
which is indicative of enzyme inactivation. This concentration also
completely prevented parasite growth; the IC50 for the growth
inhibition effect was 750–900 nM depending on the parasite
strain.
We speculate that the cytocidal action of BBMQ is mediated
mainly through the inhibition of red cell Prx2. To exclude the
effects of BBMQ on parasite-expressed proteins (P. falciparum
possesses two 2-Cys peroxiredoxins, TPx1 and TPx2; [9]) red cells
were treated with BBMQ and extensively washed prior to parasite
infection. These cells supported normal rates of merozoite
invasion. However once inside, the parasites failed to grow;
DNA synthesis and hemozoin production were impaired, nuclear
integrity was lost and viable merozoite production did not occur.
The IC50 values for BBMQ were lower in the washout
experiments compared to continuously treated cultures, indicating
that the compound may also affect parasite proteins required for
optimal growth.
It is possible that the total redox balance of the erythrocyte is
disturbed by BBMQ. However, the morphology and osmotic
fragility of cells treated with even high concentrations of the
compound (25 mM) was unchanged (data not shown). It is also
possible that other erythrocyte 2-Cys containing proteins targeted
by BBMQ are also needed for parasite growth. However Prx2 is
by far the most abundant enzyme of its class in red cells [6], and
no evidence of the parasite importing other red cell 2-Cys proteins
has been reported [16,17]. A direct requirement for red cell Prx2
in parasite growth is also consistent with previous observations that
Figure 3. Comparing the effects of continuous and washout
BBMQ treatment on P. falciparum growth. Percentage growth
inhibition of P. falciparum 3D7 (A) and K1 (B) using continuous or
washout BBMQ treatment. Data represent the mean (6 SEM) of at least
two independent experiments performed in duplicate. * indicates
p,0.01.
doi:10.1371/journal.pone.0092411.g003
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the enzyme is imported by the parasite and remains enzymatically
active within the cell [16].
Both early and late-stage developmental forms of the parasite
were highly susceptible to exogenous BBMQ treatment, and the
effect was rapid. In the case of ring-stage parasites, DNA
fragmentation (TUNEL-labeled) and loss of cell integrity were
visible within four hours exposure to BBMQ. The cytocidal effect
was similarly rapid on trophozoite stage cells. We also note that
the pyknotic appearance of the BBMQ-treated parasites is similar
to the previously reported effects of the antimalarial drug
artesunate. P. falciparum parasites treated with artesunate in culture
undergo changes resembling an arrest in growth. However upon
removal of drug, viable parasites can be recovered, suggesting the
drug induces a state of dormancy [24,25]. We have not tested if
the growth of BBMQ-treated cells is similarly recoverable. BBMQ
also has a comparably rapid and broad-spectrum activity. Indeed
the mechanism of action for artesunate includes the generation of
oxidant compounds in the parasite, via an endoperoxide moiety
[26]. Molecules with BBMQ-like actions that target oxidant
protective mechanisms (in the host cell) may therefore also be
highly effective as antimalarials.
Despite the well-reported lack of efficacy and WHO guidelines
that discourage its use, CQ continues to be used at high rates in
many African countries [27]. This ensures the ongoing existence of
CQ resistant strains. Our observations suggest a possible new
strategy to treat infections of such strains: target the Prx2 enzyme
or other oxidant protective systems in the parasite. Low (sub-
inhibitory) concentrations of BBMQ were sufficient to reduce the
CQ IC50 of normally resistant parasite strains to levels within the
normal therapeutic dose window.
We [28] and others [29] have previously proposed a novel host-
directed therapy (HDT) strategy for malaria treatment where host
proteins, rather than parasite proteins, are targeted. If such host
proteins are essential to the parasite, the inhibitors would block
parasite growth, and avoid potential drug resistance problems.
With respect to the possible toxic effects of targeting such proteins
with essential functions, it is interesting to note that homozygous
null Prx2 mice are relatively healthy and fertile. They do however
exhibit a mild anemia and splenomegaly, which is exacerbated if
Figure 4. The effects of BBMQ washout treatment on the cytocidal action of CQ. (A) Representative data of the percentage of infected red
cells categorized according to parasite stage or growth-arrested appearance after 24 hours incubation with different concentrations of CQ. Red cells
were either pretreated with BBMQ, or not treated (control), and then infected with purified trophozoites and allowed to invade and grow for
12 hours. (B) Analysis of the data in (A) with respect to proportions of mature 3D7 parasites (as a function of all parasitized cells) present in cultures
after 24 hours incubation. IC50 values for the effect of CQ on parasite maturation were 16.3 nM (control) and 1.4 nM (BBMQ). (C) Photomicrographs of
growth-arrested 3D7 parasites following CQ treatment for 24 hours (i–iii), and a healthy trophozoite stage parasite observed at the same time point
in a control culture (iv). (D) Percentage of red cells containing second-generation ring stage parasites after 48 hours incubation with CQ. IC50 values
for the effect of CQ on parasite growth with or without BBMQ pretreatment, respectively, were 3D7, 2.3 and 26 nM; K1, 51 and 313 nM. Data in B and
D represent the mean (6 SEM) of at least two independent experiments performed in duplicate. * indicates p,0.01.
doi:10.1371/journal.pone.0092411.g004
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the animals are exposed to oxidant stress-inducing compounds
[30,31]. The action of a compound like BBMQ would have an
added advantage in this context by virtue of its irreversible action;
short-term treatment would be effective for the life of the red cell
(since new protein synthesis does not occur), while synthetically
active cells, including erythrocyte progenitors, would restore the
pool of functional enzyme. Whether BBMQ or a derivative
compound may be safe to administer in vivo and produce an
antimalarial effect remains to be determined.
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